Molecular therapy for pulmonary arterial hypertension: Melatonin inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 10/February/2018, 12.02 pm

 Anti-infective Therapy: Ritonavir, an  anti-HIV drug, inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 18/February/2017,  11.55 pm
February 18, 2018
Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA)   increases the expression of tumor/metastatic suppressors RECK1 and CADM1 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 19/February/2018, 11.54 pm
February 19, 2018
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary arterial hypertension: Melatonin inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3


Significance of the study:  

This study suggests, for the first time, that  Melatoninby increasing the expression of its target gene, it may decrease, in dose-dependent manner, the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, pharmacological formulations encompassing “Melatonin or its analogues, either alone or in combination with other drugs, may be used to treat pulmonary arterial hypertension (Figure 2). Together, this study suggests that, by treating pulmonary hypertensive patients with Melatonin, one may prevent pulmonary arterial hypertension

Figure 1. Mechanistic insights into how  Melatonin inhibits the development of pulmonary hypertension through regulation of its target genes

Figure 2. The chemical structure of Melatonin


Details of the research findings: 

Idea Proposed/Formulated by:

Dr L Boominathan Ph.D.

Undisclosed mechanistic information: How Melatonin decreases the expression of Notch3 and its target gene

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L., Molecular therapy for pulmonary arterial hypertension: Melatonin inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 10/February/2018, 12.02 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.